spacer
home > ebr > winter 2020 > the future of vaccination
PUBLICATIONS
European Biopharmaceutical Review

The Future of Vaccination




Today, it is estimated that vaccines save more than 2.5 million lives each year (1). Given the tremendous success of vaccines, it may seem strange that we are facing a controversy regarding their role in modern society. Vaccines are similarly experiencing a decline in the commercial sector with some companies exiting the space and innovation lagging behind. Innovation is critical to realise the full potential of vaccines, but the current system of discovery and development may not be fostering it as well as it could.

Need for Vaccine Innovation

Influenza vaccines provide protection against infection, and importantly, decrease the associated morbidity and mortality. Nevertheless, despite protecting against 7 million illnesses in the 2017-2018 flu season alone, the average effectiveness of influenza vaccines between 2004 and 2017 was only 41%, and in some years the effectiveness dropped to as low as 10% (2-3). Moreover, the vaccine must be taken annually as it is continually updated to keep pace with the constant evolution of the influenza virus. Significant innovation in influenza vaccines has been largely absent despite the FDA approval of three new types of influenza vaccines in the last seven years – one using a recombinant antigen, another based on a mammalian cell culture manufacturing process instead of the traditional egg-based process, and a third that includes an adjuvant to boost the immune response to the vaccine (4-6). Improving the overall effectiveness of influenza vaccines is important for their yearly use as a seasonal vaccine, not only to provide better protection to the population, but also to increase influenza vaccine coverage, which was only 45% for adults during the 2018-2019 flu season in the US (7). Critically, improved influenza vaccines are also needed in response to an influenza pandemic. During an influenza pandemic, the population has little baseline immunity to the circulating influenza virus, and it is expected that two doses of the current vaccine types would be required for adequate protection. The development of more effective influenza vaccines that provide pandemic protection after a single dose could dramatically slow the spread of the infection through the population.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Scot Roberts PhD is the Chief Scientific Officer of Altimmune and has more than 24 years of experience in small molecule and biologics development in the areas of vaccines, viral vectors, and antiviral therapies. He previously served as Chief Scientific Officer for ImQuest BioSciences, where he led initiatives in cancer and antivirals. Scot also held R&D leadership positions at Wellstat Biologics Corporation, where he managed a portfolio of biologic oncology candidates, animal pharmacology programmes, and led bioassay and upstream process development. Scot has a PhD in Pharmacology and Molecular Sciences from the Johns Hopkins School of Medicine, US.
spacer
Dr Scot Roberts
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Partners with Propeller Health to Gather Accurate Data on Asthma and COPD Medication Use

Philadelphia, PA – January 07, 2020: Signant Health announced today a partnership to connect TrialMax®, the industry-leading electronic Clinical Outcome Assessment (eCOA) platform, to Propeller Health’s digital health platform for asthma and COPD (chronic obstructive pulmonary disease).
More info >>

White Papers

High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts

ILC Dover

As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
More info >>

 
Industry Events

Bio Integrates 2020

21 May 2020, Leonardo Royal Hotel London Tower Bridge UK

Bio Integrates 2020 is a one-day gathering of biotech, pharma, CDMO & CRO organisations as well as clinicians, patient groups and regulators to provide a platform to discuss the major challenges impacting the biotech sector. There will be in excess of 250 senior industry executives and 70 + speakers participating.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement